Reviva Pharmaceuticals Holdings, Inc. said cash and cash equivalents were approximately $17.5 million as of September 30, 2026, but current cash would not satisfy operating needs for 12 months, raising substantial doubt about its ability to continue as a going concern.
RVPH · Reviva Pharmaceuticals Holdings, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the consolidated financial statements are issued.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 42%
- Latest filing
- 10-Q · Nov 13
- Price history
- Dec 2020 to May 2026
Latest documents
Reviva reported a net loss of approximately $2.3 million, or $0.17 per share, for the three months ended September 30, 2026. FDA feedback on brilaroxazine is expected Q4 2026, and RECOVER-2 enrollment is targeted for 1H 2027, subject to additional financing.
Reviva Pharmaceuticals Holdings, Inc. effected a one-for-twenty reverse stock split effective March 9, 2026, then closed a public offering on March 20, 2026 that generated approximately $8.9 million in net proceeds.
At its December 18, 2026 meeting, Reviva Pharmaceuticals Holdings, Inc. will seek five director elections and approval of a reverse split from one-for-two (1:2) to one-for-one hundred (1:100). The board could implement it by December 31, 2027 without further approval.
Reviva Pharmaceuticals Holdings, Inc. asks stockholders to authorize a reverse stock split ranging from one-for-two (1:2) to one-for-one hundred (1:100) before December 31, 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RVPH
this stock
Reviva Pharmaceuticals Holdings, Inc.
|
$6.33M | — | — | — | 3.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- -7.7K sh
- Top holder
- Miller Global Investments…
- Filed
- Nov 13, 2026
- This year
- 18
Reviva Pharmaceuticals Holdings, Inc. said cash and cash equivalents were approximately $17.5 million as of September 30, 2026, but current cash would not satisfy operating needs for 12 months, raising substantial doubt about its ability to continue as a going concern.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RVPH | -54.8% | -55.4% | -96.1% | -55.2% | -93.0% |
| SPY | +2.3% | +6.6% | +12.9% | +4.1% | +9.7% |
| vs SPY | -57.1% | -62.0% | -109.0% | -59.3% | -102.7% |